Assignee
SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD
CN·10 granted patents·11 pending applications·12 citations·filing 2014–2022
Top patents by PatentIndex Score
21 records- 0188US12269886B2Tetravalent bispecific antibody against PD-1 and PD-L1SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Granted Apr 8, 2025·2 cites·10 claims
- 0281US11667717B2Antibodies binding to human IL-4R, preparation method therefor and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2019·Granted Jun 6, 2023·3 cites·12 claims
- 0378US10246484B2Method for purifying recombinant proteinSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2014·Granted Apr 2, 2019·7 cites·18 claims
- 0470US2022127362A1Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0570US2022127360A1Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0670US2022127361A1TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/TGF-beta, PREPARATION METHOD THEREFOR, AND USE THEREOFSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0761US12509528B2Antibody binding to human CD38, preparation method thereof, and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Granted Dec 30, 2025·0 cites·22 claims
- 0860US2024254232A1Trispecific antibody and preparation method therefor and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0959US2025129175A1CDC Platform AntibodySUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1058US2025066499A1Antibody binding to human cd73, preparation method therefor, and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1157US2022135686A1Antibody that binds to human pd-l1SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1256US2023312682A1SIRPalpha-FC FUSION PROTEINSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1355US2022259330A1Tetravalent bispecific antibody, preparation method therefor, and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1454US2023399394A1Antibody Binding to Human IL-33, Preparation Method Therefor, and Use ThereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1553US12351612B2Method for preparing recombinant human nerve growth factorSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2020·Granted Jul 8, 2025·0 cites·12 claims
- 1650US12319748B2Antibody binding to human HER2 and preparation method and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2019·Granted Jun 3, 2025·0 cites·18 claims
- 1750US11370836B2Monoclonal antibody binding to human IL-5, preparation method therefor and use thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2018·Granted Jun 28, 2022·0 cites·19 claims
- 1848US2023257465A1ANTI-PDL1 x EGFR BISPECIFIC ANTIBODYSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1943US11254746B2Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereofSUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2018·Granted Feb 22, 2022·0 cites·23 claims
- 2042US12384853B2Anti-HER2/PD1 bispecific antibodySUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD·Filed 2019·Granted Aug 12, 2025·0 cites·10 claims
- 2138US10738112B2Anti-human interleukin-17A monoclonal antibodySUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO LTD·Filed 2017·Granted Aug 11, 2020·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →